Shenzhen - Delayed Quote CNY

Renhe Pharmacy Co.,Ltd (000650.SZ)

5.52
+0.02
+(0.36%)
At close: May 23 at 3:04:54 PM GMT+8
Loading Chart for 000650.SZ
  • Previous Close 5.50
  • Open 5.45
  • Bid 5.52 x --
  • Ask 5.53 x --
  • Day's Range 5.50 - 5.58
  • 52 Week Range 5.10 - 7.03
  • Volume 20,482,383
  • Avg. Volume 15,195,201
  • Market Cap (intraday) 7.728B
  • Beta (5Y Monthly) 0.59
  • PE Ratio (TTM) 16.24
  • EPS (TTM) 0.34
  • Earnings Date --
  • Forward Dividend & Yield 0.20 (3.62%)
  • Ex-Dividend Date Jul 8, 2024
  • 1y Target Est --

Renhe Pharmacy Co.,Ltd produces and sells pharmaceutical products. It offers Chinese and western medicines and raw materials; and health-related products, including oral solid preparations and liquid preparations, large-volume and small-volume injections, external lotions, liniments, suppositories, ointments, and other dosage forms of drugs and health-related products. The company was founded in 1996 and is headquartered in Nanchang, China.

www.renheyaoye.com

5,394

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 000650.SZ

View More

Performance Overview: 000650.SZ

Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

000650.SZ
4.17%
SSE Composite Index (000001.SS)
0.10%

1-Year Return

000650.SZ
16.29%
SSE Composite Index (000001.SS)
7.44%

3-Year Return

000650.SZ
2.27%
SSE Composite Index (000001.SS)
6.40%

5-Year Return

000650.SZ
9.38%
SSE Composite Index (000001.SS)
19.00%

Compare To: 000650.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 000650.SZ

View More

Valuation Measures

Annual
As of 5/23/2025
  • Market Cap

    7.73B

  • Enterprise Value

    4.22B

  • Trailing P/E

    16.42

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.01

  • Price/Book (mrq)

    1.22

  • Enterprise Value/Revenue

    1.10

  • Enterprise Value/EBITDA

    5.57

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.27%

  • Return on Assets (ttm)

    5.30%

  • Return on Equity (ttm)

    8.00%

  • Revenue (ttm)

    3.82B

  • Net Income Avi to Common (ttm)

    468.92M

  • Diluted EPS (ttm)

    0.34

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.84B

  • Total Debt/Equity (mrq)

    0.04%

  • Levered Free Cash Flow (ttm)

    197.74M

Research Analysis: 000650.SZ

View More

Company Insights: 000650.SZ

Research Reports: 000650.SZ

View More

People Also Watch